ADVISORY, May 6, 2015 (GLOBE NEWSWIRE) --
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform, will visit the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO), which will occur today, May 6.
In honor of the occasion, James Noble, Chief Executive Officer will ring the Opening Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Thursday, May 7, 2015 – 9:15 a.m. to 9:30 a.m. ET
Adaptimmune Therapeutics Media Contact:
M: +44 (0)7710 304249
T: +44 (0)1235 430036
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/
A webcast of the Nasdaq Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Adaptimmune Therapeutics plc (Nasdaq:ADAP):
Adaptimmune is focused on the use of T cell therapy to treat cancer. Established in 2008 with a research base in Oxford, UK and a clinical base in Philadelphia, US, the company aims to utilize the body’s own machinery – the T cell – to target and destroy cancerous cells by using engineered, increased affinity T cell receptor (TCRs) as a means of strengthening natural patient T cell responses. Adaptimmune’s lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In September, the company completed a $104 million Series A financing round. Adaptimmune has over 100 staff. For more information: http://www.adaptimmune.com
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of approximately $9.5 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.